Pulmonary hypertension: Diagnosis and management

Mayo Clinic Proceedings

Volumn 84, Issue 2, 2009, Pages 191-207

  McGoon, Michael D ^a   Kane, Garvan C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DECONGESTIVE AGENT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ESTROGEN DERIVATIVE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; INFLUENZA VACCINE; LOOP DIURETIC AGENT; METOLAZONE; MILRINONE; NITRATE; PHOSPHODIESTERASE V INHIBITOR; PNEUMOCOCCUS VACCINE; POTASSIUM SPARING DIURETIC AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; UNINDEXED DRUG; UNIPROST; WARFARIN; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; ANTIHYPERTENSIVE AGENT; BMPR2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOTHELIN RECEPTOR; PHOSPHODIESTERASE INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGINA PECTORIS; APOPTOSIS; ASCITES; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG COST; DYSPEPSIA; EDEMA; EPISTAXIS; ERECTILE DYSFUNCTION; ESSENTIAL FATTY ACID DEFICIENCY; EXERCISE; FLUSHING; GENETIC ANALYSIS; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; HYPOXEMIA; INJECTION SITE REACTION; INSURANCE; LEG PAIN; LUNG ARTERY PRESSURE; LUNG INFECTION; NAUSEA; NOSE CONGESTION; OUTCOME ASSESSMENT; PATHOLOGY; PREGNANCY; PROSTACYCLIN DEFICIENCY; PULMONARY HYPERTENSION; RASH; RECEPTOR BLOCKING; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SYNCOPE; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; VEIN THROMBOSIS; ALGORITHM; ARTICLE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; GENETICS; HEALTH INSURANCE; HOSPITALIZATION; PATHOPHYSIOLOGY; UNSTABLE ANGINA PECTORIS;

ACTIVIN RECEPTORS, TYPE II; ALGORITHMS; ANGINA, UNSTABLE; ANTIHYPERTENSIVE AGENTS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; EXERCISE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INSURANCE COVERAGE; INSURANCE, HEALTH; PHOSPHODIESTERASE INHIBITORS; PREGNANCY; RECEPTORS, ENDOTHELIN; SEVERITY OF ILLNESS INDEX; SYNCOPE;

EID: 61449123995     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.2.191     Document Type: Conference Paper

References (101)

1. Humbert M. Update in pulmonary arterial hypertension 2007. Am J Respir Crit Care Med. 2008;177(6):574-579.
2. Chin KM, Rubin LJ. Pulmonary arterial hypertension [published correction appears in J Am Coll Cardiol. 2008 Jul 8;52(2):169]. J Am Coll Cardiol. 2008;51(16):1527-1538.
3. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):1-22.
4. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol. 2007;2:369-399.
5. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114(13):1417-1431.
6. Newman JH, Fanburg BL, Archer SL, et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases Workshop. Circulation. 2004;109(24):2947-2952.
7. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 suppl):78S-92S.
8. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(suppl 1):14S-34S.
9. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243-2278.
10. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(suppl 1):35S-62S.
11. Voelkel NF, Cool C. Pathology of pulmonary hypertension. Cardiol Clin. 2004;22(3):343-351.
12. McLoughlin P, Hyvelin JM, Howell K. Pulmonary hypertension [letter]. N Engl J Med. 2005;352(4):418-419.
13. Newman JH. Pulmonary hypertension. Am J Respir Crit Care Med. 2005 Nov;172(9):1072-1077. Epub 2005 Jun 30.
14. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917-1928.
15. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107(2):216-223.
16. Lane KB, Machado RD, Pauciulo MW, et al; International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension [letter]. Nat Genet. 2000;26(1):81-84.
17. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000 Sep;67(3):737-744. Epub 2000 Jul 20.
18. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004;43(12, suppl S):33S-39S.
19. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA III, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;152(1):93-97.
20. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001;345(5):325-334.
21. Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia [published correction appears in J Med Genet. 2004;41(7):576]. J Med Genet. 2003;40(12):865-871.
22. Eddahibi S, Humbert M, Fadel E, et al. Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest. 2002;121(3)(suppl):97S-98S.
23. Marcos E, Fadel E, Sanchez O, et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 2004 May 14;94(9):1263-1270. Epub 2004 Apr 1.
24. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108(8):1141-1150.
25. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70-75.
26. Cacoub P, Dorent R, Maistre G, et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol. 1993;71(5):448-450.
27. Langleben D, Dupuis J, Hirsch A, et al. Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. Chest. 2005;128(6)(suppl):622S.
28. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732-1739.
29. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214-221.
30. Demoncheaux EAG, Higenbottam TW, Kiely DG, et al. Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res. 2005 Mar-Apr;42(2):133-136. Epub 2005 Jan 21.
31. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99(3):249-254.
32. Yuan JX, Aldinger AM, Juhaszova M, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1998;98(14):1400-1406.
33. Weir EK, Reeve HL, Huang JM, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996;94(9):2216-2220.
34. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22(2):358-363.
35. Tuder RM, Groves BM, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144(2):275-285.
36. Altman R, Scazziota A, Rouvier J, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol. 1996;19(7):549-554.
37. Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coag Fibrinolysis. 1998;9(2):107-117.
38. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J. 1998;12(6):1446-1449.
39. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest. 1996;110(3):710-717.
40. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12, suppl S):5S-12S.
41. Barst RJ, McGoon MD, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12)(suppl S):40S-47S.
42. Weir EK, Obreztchikova M, Hong Z. Fenfluramine: riddle or Rosetta stone [editorial]? Eur Respir J. 2008;31(2):232-235.
43. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases [published correction appears in Eur Respir J. 2008;31(4):912]. Eur Respir J. 2008 Feb;31(2):343-348. Epub 2007 Oct 24.
44. Abenhaim L, Moride Y, Brenot F, et al; International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335(9):609-616.
45. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006;130(6):1657-1663.
46. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580-587.
47. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81.
48. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest. 2006;130(2):545-552.
49. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc. 1985;60(1):16-25.
50. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation. 1987;76(1):135-141.
51. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005 Jun 14;111(23):3105-3111. Epub 2005 Jun 6.
52. Barst RJ, Rubin LJ, Long WA, et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-301.
53. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-788.
54. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
55. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med. 2000;132(6):425-434.
56. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000;162(5):1846-1850.
57. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003 Feb 15;167(4):580-586. Epub 2002 Nov 21.
58. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation. 1997;63(4):604-606.
59. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999;130(9):740-743.
60. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99(14):1858-1865.
61. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol. 1999;34(4):1184-1187.
62. Simonneau G, Barst RJ, Galie N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-804.
63. Tapson VF, Gomberg-Maitland M, Mclaughlin VV, et al. Safety and efficacy of intravenous treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label 12-week trial. Chest. 2006;129(3):683-688.
64. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195-1203. Epub 2006 Aug 9.
65. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005 Dec 15;172(12):1586-1589. Epub 2005 Sep 8.
66. Olschewski H, Simonneau G, Galiè N, et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-329.
67. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342(25):1866-1870.
68. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288:1119-1123.
69. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension [published correction appears in N Engl J Med. 2002;346(16):1258]. N Engl J Med. 2002;346(12):896-903.
70. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension [published correction appears in Eur Respir J. 2005;25(5):942]. Eur Respir J. 2005;25(2):244-249.
71. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27(5):589-595. Epub 2006 Jan 23.
72. Galiè N, Badesch DB, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529-535.
73. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities [published online ahead of print September 23, 2008]. Chest. doi:10.1378/chest.08-1028. http://chestjournal.org/cgi/content/abstract/chest.08-1028v1. Accessed December 8, 2008.
74. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension [published correction appears in N Engl J Med. 2006;354(22):2400-2401]. N Engl J Med. 2005;353(20):2148-2157.
75. Reichenberger F, Pepke-Zaba J, McNeil K, Parameshwar J, Shapiro LM. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax. 2003;58(9):797-800.
76. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. J Am Coll Cardiol. 1998;32(2):297-304.
77. Bonderman D, Fleischmann D, Prokop M, Klepetko W, Lang IM. Left main coronary artery compression by the pulmonary trunk in pulmonary hypertension. Circulation. 2002;105(2):265.
78. Dodd JD, Maree A, Palacios I, et al. Left main coronary artery compression syndrome: evaluation with 64-slice cardiac multidetector computed tomography. Circulation. 2007;115(1):e7-e8.
79. Kawut SM, Silvestry FE, Ferrari VA, et al. Extrinsic compression of the left main coronary artery by the pulmonary artery in patients with long-standing pulmonary hypertension. Am J Cardiol. 1999;83(6):984-986.
80. Lindsey JB, Brilakis ES, Banerjee S. Acute coronary syndrome due to extrinsic compression of the left main coronary artery in a patient with severe pulmonary hypertension: successful treatment with percutaneous coronary intervention. Cardiovascr Revasc Med. 2008;9(1):47-51.
81. Mesquita SM, Castro CR, Ikari NM, Oliveira SA, Lopes AA. Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. Am J Med. 2004;116(6):369-374.
82. Rich S, McLaughlin VV, O'Neill W. Stenting to reverse left ventricular ischemia due to left main coronary artery compression in primary pulmonary hypertension. Chest. 2001;120(4):1412-1415.
83. Mikhail GW, Gibbs JSR, Yacoub MH. Pulmonary and systemic arterial pressure changes during syncope in primary pulmonary hypertension. Circulation. 2001;104(11):1326-1327.
84. McQuillan BM, Picard MH, Leavitt M, Weymann AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001;104(23):2797- 2802.
85. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006 Oct;114(14):1482-1489. Epub 2006 Sep 18.
86. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler- catheterization study in 127 patients. J Am Coll Cardiol. 1985;6(4):750-756.
87. Rich S, D'Alonzo GE, Dantzker DR, Levy PS. Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. Am J Cardiol. 1985;55(1):159-163.
88. Frantz RP, Benza RL, Kjellström B, et al. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2008 Jul;27(7):780-788. Epub 2008 Jun 2.
89. Parambil JG, McGoon MD. Pregnancy and pulmonary hypertension. In: Oakley C, Warnes CA, eds. Heart Disease in Pregnancy. Malden, MA: Blackwell Publishing; 2007:59-78.
90. O'Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):169-185.
91. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353-359.
92. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec;174(11):1257-1263. Epub 2006 Aug 31.
93. Simonneau G, Rubin LJ, Galiè N et al; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521-530.
94. United Therapeutics. TRIUMPH-1 trial of Viveta in pulmonary arterial hypertension meets primary endpoint. November 1, 2007. http://ir.unither.com/ releasedetail.cfm?ReleaseID=272478. Accessed January 12, 2009.
95. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol. 2005 Nov 1;96(9):1334-1336. Epub 2005 Sep 16.
96. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24(6):1007-1010.
97. Medical News Today. FREEDOM-C trial of oral treprostinil in pulmonary arterial hypertension fails to meed primary endpoint. http://www. medicalnewstoday.com/articles/129702.php. Accessed January 12, 2009.
98. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26(5):858-863.
99. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Circulation. 2006;114(17):1883-1891.
100. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL Registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008;83(8):923-931.
101. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006 May 1;173(9):1023-1030. Epub 2006 Feb 2.